Investor Relations

Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Up 1.06 (2.28%)
Data as of 01/16/18 10:08 a.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $47.64 with a 52 week high of $47.71 and a 52 week low of $19.95.
Recent NewsMore >>
Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTH
Ascendis Pharma Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone for Pediatric Growth Hormone Deficiency
Ascendis Pharma A/S Announces Participation in 36th Annual J.P. Morgan Healthcare Conference
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma

Data provided by Nasdaq. Minimum 15 minutes delayed.